ArticleFrontiers in immunology2026
Identification and validation of a prognostic signature comprising inflammation and pyroptosis-related genes in oral squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) represents a common malignancy characterized by significant morbidity and mortality rates, highlighting the critical necessity for novel therapeutic approaches. Consequently, investigating differentially expressed genes linked to inflammation and pyroptosis may identify potential prognostic biomarkers and therapeutic targets. Methods: To address this research gap, our study utilized an extensive bioinformatics approach by analyzing the Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma (TCGA-HNSC) dataset through differential expression analysis to identify genomic features associated with OSCC. Subsequent analyses included Gene Ontology and pathway enrichment assessments, along with survival analyses using Cox regression models, to evaluate the prognostic significance of the identified differentially expressed genes. Furthermore, immune infiltration analysis and somatic mutation assessments were conducted to elucidate the relationship between immune cell types and key prognostic genes. Additionally, copy number variation analysis was performed to highlight genomic alterations associated with immune-related and prognostic-related differentially expressed genes(DEGs). Results: Our analysis identified a total of 3,495 differentially expressed genes, among which 53 immune-related and prognosis-related differentially expressed genes demonstrated a significant correlation with the prognosis of OSCC. Immune infiltration analysis further revealed the presence of 28 immune cell types within OSCC samples, with a notable prevalence of activated CD8 T cells and regulatory T cells, underscoring their association with critical prognostic genes. Additionally, pathway analysis highlighted the activation of cytokine signaling pathways and their associations with processes relevant to systemic lupus erythematosus. A prognostic risk model derived from these findings effectively stratified patients based on overall survival, identifying four key genes- Conclusion: This study established a novel OSCC prognostic risk model based on inflammation- and pyroptosis-related interactive genes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.